Is Compounded GLP-1 Safe? A Doctor's Honest Take

What “compounded” really means

Compounding is when a licensed pharmacy prepares a medication to fit a specific need, instead of using a mass-produced version from a drug manufacturer. This is not a loophole or a shortcut. Pharmacies have compounded medications for a very long time, and it’s a normal, legitimate part of medicine.

In the United States, these pharmacies fall into two regulated types. A 503A pharmacy compounds for individual patients based on a prescription. A 503B pharmacy is an outsourcing facility held to stricter manufacturing standards. Both answer to a governing body and operate under oversight. That regulation matters, and we’ll come back to why.

What the evidence actually says

Here’s where I want to be straight with you. The research does not show that compounded GLP-1 medications are inherently unsafe. What it shows is that their safety is less predictable than the FDA-approved versions.

The reason is simple. FDA-approved GLP-1 drugs have been through large clinical trials and years of tracking, so we know what to expect from them. Compounded versions don’t go through that same review for potency (how strong the dose actually is), purity (whether it’s clean), and consistency (whether every batch is the same). The FDA has logged adverse events — unwanted reactions — tied to compounded semaglutide and tirzepatide, some serious enough to require hospitalization. But we don’t have clean head-to-head data comparing them to brand-name products.

So “unknown” is the accurate word here — not “unsafe.” Those are two different things, and the difference matters.

The real risk is the vial, not the molecule

This is the part most people get wrong. The biggest documented risks with these medications don’t come from the drug itself. They come from how it’s delivered.

Brand-name GLP-1 pens are pre-filled and pre-measured — you dial a dose and inject. Many compounded products come in a vial, where you draw the dose yourself with a syringe. That’s where errors happen. People confuse units with milliliters and accidentally draw 10 to 20 times the dose they intended. That’s not a small mistake.

But here’s the nuance I want you to understand: this is not unique to compounding, and a vial is not automatically dangerous. Think about insulin. Millions of people draw insulin from multi-dose vials at home every day. Insulin is arguably more demanding, you dose it far more often, a single vial holds many doses, and a mistake can drop your blood sugar to a dangerous level within minutes. We still trust patients to do it, because we teach them how.

The danger lives in how a medication is handled and whether you’ve been properly taught, not in where it came from.

How a good practice removes that risk

A vial is only dangerous when nobody teaches you how to use it. We solve that problem the same way medicine has always solved it — with education and supervision.

When we start a patient on an injectable, we counsel them during the visit. We provide videos and step-by-step instructions on how to draw the right dose, how to inject cleanly, how to keep the vial from spoiling. None of this is new — it’s exactly how we’ve taught patients to manage insulin for generations.

We’re also careful about concentration. We don’t dispense ultra-concentrated, multi-month vials. A vial packed with a very high dose per milliliter is exactly where the worst overdose errors happen. By dispensing lower-concentration vials, we leave far less room for a dangerous mistake. Safe vial use is a teaching problem, and it’s a solvable one.

The question to ask your provider

This is what I actually want you to walk away with. Before you start a GLP-1 medication from anyone, ask the right questions.

First, are you seeing a real human clinician? An MD, DO, nurse practitioner, or physician assistant — a person who connects with you and earns your trust. Trust is not a nice-to-have here. It’s part of safe care.

Second, where does that medication come from? It should be sourced from a U.S.-based pharmacy that is 503A or 503B and operating under regulatory oversight. And ask the question almost nobody thinks to ask: What does my provider do to vet that pharmacy — and to keep watching it over time? A good answer to that single question tells you most of what you need to know.

A chatbot is not standard of care

I’ll say this plainly. A licensed human being should be guiding your GLP-1 therapy. Not an algorithm, not a chatbot, not a form you fill out that spits back a prescription.

Telehealth is completely fine — a physician can guide you just as well over video as in person. The issue isn’t the screen. The issue is whether there’s a real clinician on the other side of it. A human brings judgment, personal experience, and the kind of insight that catches a problem before it becomes one. Software doesn’t do that. To me, having a real person involved isn’t a luxury. It’s the standard of care.

The fair question worth asking

Here’s something worth sitting with. During the recent shortages, professional groups accepted compounded GLP-1 medications made by these same pharmacies and prescribed by these same providers. Now that the shortage has eased, the tone has shifted toward avoiding them.

So it’s fair to ask: if the pharmacy is the same and the provider is the same, what actually changed about the safety? It’s an honest question, and I think patients deserve to think it through for themselves.

Bottom line: Are compounded GLP-1 safe?

Compounded GLP-1 medications are not the danger. Unsupervised, poorly sourced, self-injected medication with nobody guiding you — that’s the danger. Know your provider. Know where they source from and how they vet it. And make sure there’s a real human guiding your care. Get those things right, and “compounded” stops being a scary word.

References

1. American Diabetes Association Professional Practice Committee. Pharmacologic Approaches to Glycemic Treatment: Standards of Care in Diabetes—2026. Diabetes Care. 2026;49(Suppl 1):S183–S215. doi:10.2337/dc26-S009.

2. Neumiller JJ, Bajaj M, Bannuru RR, et al. Compounded GLP-1 and Dual GIP/GLP-1 Receptor Agonists: A Statement From the American Diabetes Association. Diabetes Care. 2025;48(2):177–181. doi:10.2337/dci24-0091.

3. US Food and Drug Administration. FDA’s Concerns With Unapproved GLP-1 Drugs Used for Weight Loss. US Food and Drug Administration; 2025.

4. Mattingly TJ 2nd, Conti RM. Marketing and Safety Concerns for Compounded GLP-1 Receptor Agonists. JAMA Health Forum. 2025;6(1):e245015. doi:10.1001/jamahealthforum.2024.5015.

5. Chetty AK, Chillakanti M, Ramachandran R, Ross JS, Chen AS. Online Advertising of Compounded Glucagon-Like Peptide-1 Receptor Agonists. JAMA Health Forum. 2025;6(1):e245018. doi:10.1001/jamahealthforum.2024.5018.

6. Belcourt J, Sapowadia A, White CM. Compounded Semaglutide and Tirzepatide Products Use Unique Formulations but Efficacy and Safety Largely Unknown. Ann Pharmacother. 2026. doi:10.1177/10600280261421979.

About the author

Edward Orshansky, M.D. is a board-certified Family Medicine physician and a member of the Alpha Omega Alpha Honor Medical Society, with more than 10 years of experience across Hospital Medicine, Urgent Care, and Primary Care. He is the Founder of formidableMD. Having lost 85 pounds himself, he understands this work from both sides of the exam table. His mission is simple: help patients reach their healthiest selves before they ever end up as hospital patients. His focus is weight management, longevity, and hormonal health. You can find his professional profile on Doximity.

This article is for educational purposes only and does not constitute medical advice. Always consult a qualified healthcare provider before making changes to your health regimen.